-2.10 | -2.05%
ALEXION PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2013 is essentially unchanged when compared to the same period a year ago. The company has grown sales and net income significantly, outpacing the average growth rates of competitors within its industry. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 4.55 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 72.26% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
| Income Statement | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Net Sales ($mil) | 338.94 | 244.73 |
| EBITDA ($mil) | 126.47 | 89.59 |
| EBIT ($mil) | 120.21 | 83.71 |
| Net Income ($mil) | 82.22 | 45.41 |
| Balance Sheet | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Cash & Equiv. ($mil) | 1022.96 | 359.39 |
| Total Assets ($mil) | 2685.88 | 2017.46 |
| Total Debt ($mil) | 149.0 | 355.0 |
| Equity ($mil) | 2090.05 | 1213.28 |
| Profitability | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Gross Profit Margin | 91.41 | 90.81 |
| EBITDA Margin | 37.31 | 36.6 |
| Operating Margin | 35.47 | 34.21 |
| Sales Turnover | 0.46 | 0.43 |
| Return on Assets | 10.85 | 9.61 |
| Return on Equity | 13.95 | 15.98 |
| Debt | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Current Ratio | 5.24 | 2.3 |
| Debt/Capital | 0.07 | 0.23 |
| Interest Expense | 1.17 | 2.29 |
| Interest Coverage | 102.65 | 36.6 |
| Share Data | Q1 FY13 | Q1 FY12 |
|---|---|---|
| Shares outstanding (mil) | 195.06 | 186.89 |
| Div / share | 0.0 | 0.0 |
| EPS | 0.41 | 0.23 |
| Book value / share | 10.72 | 6.49 |
| Institutional Own % | n/a | n/a |
| Avg Daily Volume | 1809044.0 | 1489657.0 |
BUY. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 32.50 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 19.08. For additional comparison, its price-to-book ratio of 9.50 indicates a significant premium versus the S&P 500 average of 2.44 and a discount versus the industry average of 9.88. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
| Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALXN 70.22 | Peers 32.50 | ALXN 50.62 | Peers 48.70 | |||||||||||||||||||||
|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations. ALXN is trading at a significant premium to its peers. |
Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. ALXN is trading at a valuation on par to its peers. |
|||||||||||||||||||||||
| Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
| ALXN 31.04 | Peers 31.25 | ALXN 0.54 | Peers 0.70 | |||||||||||||||||||||
|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations. ALXN is trading at a premium to its peers. |
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. ALXN trades at a discount to its peers. |
|||||||||||||||||||||||
| Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
| ALXN 9.50 | Peers 9.88 | ALXN 45.00 | Peers 5.98 | |||||||||||||||||||||
|
Average. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. ALXN is trading at a valuation on par with its peers. |
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. ALXN is expected to have an earnings growth rate that significantly exceeds its peers. |
|||||||||||||||||||||||
| Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
| ALXN 16.17 | Peers 513.82 | ALXN 42.49 | Peers 69.95 | |||||||||||||||||||||
|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. ALXN is trading at a significant discount to its industry on this measurement. |
Lower. A sales growth rate that trails the industry implies that a company is losing market share. ALXN significantly trails its peers on the basis of sales growth |
|||||||||||||||||||||||
